戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              4AP applied to the double mutant blocked the final trans
2                                              4AP binds to exposed K(+) channels in demyelinated axons
3                                              4AP promoted a pattern of firing which was observed, alb
4  than 4AP; and 2-trifluoromethyl-4-AP (2CF(3)4AP) was found to be about 60-fold less active.
5 oromethyl-4-aminopyridine (3MeO4AP and 3CF(3)4AP) were found to be about 3- to 4-fold less potent tha
6 d in gating currents, is almost normal for a 4AP-occupied channel; only the final opening transition
7 , and brain derived neurotrophic factor in a 4AP dose dependent manner.
8 zygotes was tested directly by administering 4AP while recording force produced by failing motor unit
9                                     Although 4AP increased peak forces during unit tetanic activation
10 ery and optimization of a 4-aminopiperidine (4AP) scaffold targeting the assembly stages of the HCV l
11                    The drug 4-aminopyridine (4AP) blocks voltage-dependent potassium conductances and
12 sium channel blocking agent 4-aminopyridine (4AP) can sometimes cause ectopic activity in demyelinati
13              The convulsant 4-aminopyridine (4AP) facilitates the synchronous firing of interneurons
14                             4-aminopyridine (4AP) is a potassium (K(+)) channel blocker used clinical
15                             4-Aminopyridine (4AP) is a specific blocker of voltage-gated potassium ch
16 t a model for the action of 4-aminopyridine (4AP) on K channels.
17 investigated the effects of 4-aminopyridine (4AP) on neuronal activity and associated neurogenesis.
18 enomenon, and drugs such as 4-aminopyridine (4AP), which target K(+) channels in demyelinated axons,
19 culline methiodide (BMI) or 4-aminopyridine (4AP).
20 l types were also found for 4-aminopyridine (4AP).
21 e potassium channel blocker 4-aminopyridine (4AP).
22 n the sustained delivery of 4-Aminopyridine (4AP, molecular weight 94.1146 g/mol), a potassium-channe
23            These nerve guidance conduits and 4AP sustained delivery may serve as an attractive strate
24 zed TTX-sensitive sodium current (I(Na)) and 4AP-sensitive and TEA-resistant potassium current (I(K))
25  synchronized IPSPs in CA3 cells elicited by 4AP in the presence of ionotropic glutamate receptor blo
26 or units could be significantly increased by 4AP, whereas no effect was observed in a nonfailing moto
27 its in HCSMA homozygotes can be increased by 4AP.
28 conclude that the ectopic spiking induced by 4AP is generated by membrane potential oscillations asso
29                    Once in the open channel, 4AP's major action is to bias the activation gate toward
30 sed a total of 30 +/- 2% of the encapsulated 4AP in the first 7 days.
31 dy, we determined whether and to what extent 4AP could enhance muscle force production in HCSMA.
32                        SqKv1A's affinity for 4AP was poor at rest and increased after activation, whe
33         Unexpectedly, seizure-like events in 4AP were desynchronous events, both in comparison with i
34 nchronized interneuron oscillatory firing in 4AP.
35 ns, both in the presence and absence of 5 mM 4AP.
36              Here, we investigate four novel 4AP derivatives containing methyl (-CH(3)), methoxy (-OC
37                               The ability of 4AP to increase force in failing units may be related to
38 t [(18)F]3F4AP, a radiofluorinated analog of 4AP, also binds to K(V)1 channels and can be used as a P
39                      Multiple derivatives of 4AP capable of blocking K(+) channels have been reported
40                                The effect of 4AP is well modeled as a selective block of the final ga
41 n both the initiation and the maintenance of 4AP-facilitated inhibitory circuit oscillations.
42 the enzyme responsible for the metabolism of 4AP and 3F4AP.
43                            Possible sites of 4AP action are considered.
44 cations, arterial perfusion of either BMI or 4AP induced focal limbic SLEs.
45                  Bursts in 4-amino-pyridine (4AP) were highly synchronous events.
46                                     Systemic 4AP (1-2 mg/kg) increased nerve-evoked whole muscle twit
47  to be approximately 7-fold more potent than 4AP and 3F4AP; 3-methoxy- and 3-trifluoromethyl-4-aminop
48 nd to be about 3- to 4-fold less potent than 4AP; and 2-trifluoromethyl-4-AP (2CF(3)4AP) was found to
49                 Our studies demonstrate that 4AP increases neuronal activity in 3-month-old cerebral
50                              We propose that 4AP, like tetraethylammonium ion and other quaternary am
51  an SAR campaign, several derivatives of the 4AP series have been identified with increased potency a
52 on and infectivity studies indicate that the 4AP chemotype inhibits the assembly and release of infec
53           5Me3F4AP has comparable potency to 4AP and the PET tracer 3-fluoro-4-aminopyridine (3F4AP).
54 rest and increased after activation, whereas 4AP block occurred much more readily at rest with native